ab117596 reacts with 80-90% human peripheral T lymphocytes and medullary thymocytes. The monoclonal antibody does not react with B-cells, monocytes,
granulocytes and platelets. The monoclonal antibody is mitogenic for resting T lymphocytes and it blocks the cytolytic activity of CTL clones.
This antibody recognizes 22/26/30 kD MW lymphocyte surface molecules associated with the T cell antigen receptor complex. Reacts with 85% of peripheral blood T lymphocytes, 70% of thymocytes, the majority of T cell chronic lymphocytic leukaemias, Sezary leukaemias and approximately 70% of acute lymphoblastic leukaemias of T cell origin.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use 5µl for 106 cells.
ab126036 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
The CD3 complex mediates signal transduction.
Defects in CD3D are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)/B(+)/NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.